CBD for Dog Lymphoma: Comfort Care During Cancer Treatment
Quick Answer: While CBD cannot treat lymphoma, many pet owners report that it may help support comfort during cancer treatment...
Read moreAffiliate Disclosure: This post contains affiliate links. We may earn a commission if you purchase through our links, at no extra cost to you.
Cushing’s disease (hyperadrenocorticism) is an endocrine disorder where the body produces excess cortisol. It’s common in older dogs and causes hair loss, weakness, excessive thirst, and increased appetite. While CBD isn’t a cure, it may support quality of life during medical management.
Cushing’s disease causes systemic inflammation. CBD’s anti-inflammatory properties may help reduce associated discomfort and support skin health affected by the condition.
Many dogs with Cushing’s become depressed or anxious. CBD may help lift mood and promote a more comfortable emotional state.
Cushing’s dogs often sleep poorly. CBD may promote better rest, which is crucial for recovery and quality of life.
Cushing’s disease requires veterinary treatment with medications like mitotane or trilostane. CBD should complement, never replace, these essential treatments. Work closely with your vet to integrate both approaches safely.
A typical dose is 2-5mg CBD per pound of body weight daily. You may see benefits within 2-4 weeks. Adjust based on your dog’s response and vet recommendations.
For dogs with Cushing’s, avoid products with added sugars or excessive calories, as Cushing’s dogs often struggle with weight management. Look for clean, simple formulations.
Keep detailed records of your dog’s energy, appetite, skin condition, and overall well-being. This helps you and your vet determine if CBD is truly benefiting your dog.
Cushing’s dogs are prone to secondary skin infections. CBD oil can be applied topically to support healing of problem areas, in addition to internal supplementation.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Pets’ endocannabinoid systems respond to CBD similarly to humans, though with different metabolism and sensitivity thresholds. Research on pet CBD grows yearly, with veterinary schools now researching cannabinoid therapy. While long-term safety studies are ongoing, short-term use shows excellent safety profiles with minimal side effects in most pets.
Start with conservative doses and monitor your pet closely. For anxiety or mild pain: 1-2mg per 10 lbs daily. For moderate issues: 2-5mg per 10 lbs daily. For severe conditions: up to 5mg per 10 lbs with veterinary guidance. Divide daily dose into morning and evening for consistent symptom control. Track dose and response in a log to optimize over time.
Pet-formulated CBD oils are most popular—easy to dose, quick absorption, and adjustable. CBD treats offer convenience for picky eaters. Topical options work best for localized pain or skin issues. Avoid human products with added ingredients, sweeteners, or flavoring that may upset pet digestion. Always verify third-party testing and contact manufacturers with questions about pet formulations.
CBD works synergistically with traditional veterinary care. For pain: combine with appropriate pain medications as approved by your vet. For anxiety: pair with training, desensitization, and calming environment changes. For skin issues: use with appropriate medicated shampoos and allergen avoidance. CBD enhances the effectiveness of comprehensive care plans.

Interested in finding out more about what’s happening in the world of CBD and Medicinal Cannabis?
Head to CBD World News for the latest scientific research, clinical trials, and business news.
Abstract: Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that...
Read moreCredits: Albert Batalla†, Hella Janssen†, Shiral S. Gangadin and Matthijs G. Bossong († These authors contributed equally to this work.)...
Read moreAuthors: Kimberly A. Babson1 & James Sottile 2 & Danielle Morabito1 Publish Date: 27 March 2017 Published by: Springer Science+Business...
Read more